This article is a correction to:
Light-enhanced VEGF121/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment
Ane Sager Longva
Kristian Berg
Anette Weyergang- Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
A Corrigendum on
Light-enhanced VEGF121/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment
By Longva AS, Berg K and Weyergang A (2023) Front. Immunol. 14:1278000. doi: 10.3389/fimmu.2023.1278000
In the published article, there was an error in Figure 3 as published. 3C has wrongly also been inserted as 3D resulting in 3C showing the same figure as 3C. The figure legend is correct. The corrected Figure 3 appear below.
Figure 3
Figure 3 VEGF121/rGel-PCI induces secretion of DAMP signals from CT26 cells. (A) Relative cell viability (MTT) 48 hrs post VEGF121/rGel-PCI with indicated controls. (B) Normalized ATP secretion (bioluminescence assay) 24 and 48 hrs post VEGF/Gel-PCI with indicated controls. (C, D) HSP90 and HMGB1 secretion (quantification of western blots) 24 and 48 hrs post VEGF121/rGel-PCI with indicated controls. The graphs show averages of 3 independent experiments with error bars indicating SD. Bar labeled with * indicate p < 0.05 as compared to non-treated control (NT) (t-test). Significance between two treatments is indicated with * and dotted line (t-test). ** indicate significance with paired t-test. (E) Representative western blots of 3 independent experiments of HSP90 and MHGB1 in cell media harvested 24 and 48 hrs post treatment. VEGF121/rGel-PCI was performed with the same light dose as used with PDT while PDThigh was executed at a higher light dose..
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: immune check point inhibitor (ICI), photodynamic therapy, photochemical internalization (PCI), vascular targeting, immunogenic cell death (ICD), targeted toxin, vascular endothelial growth factor
Citation: Longva AS, Berg K and Weyergang A (2024) Corrigendum: Light-enhanced VEGF121/rGel induce immunogenic cell death and increase the antitumor activity of αCTLA4 treatment. Front. Immunol. 14:1359973. doi: 10.3389/fimmu.2023.1359973
Received: 22 December 2023; Accepted: 28 December 2023;
Published: 09 January 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Longva, Berg and Weyergang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anette Weyergang, anette.weyergang@rr-research.no